Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Can J Respir Ther ; 59: 20-25, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36741307

RESUMO

Introduction: The coronavirus Severe Acute Respiratory Syndrome Coronavirus Type 1 induces a severe respiratory disease, coronavirus disease 2019 (COVID-19). After Severe Acute Respiratory Syndrome Coronavirus Type 1 and Middle East Respiratory Syndrome infection, increased post-traumatic stress disorder (PTSD) rates were described. Methods: This single-centred, prospective study aimed to evaluate the rates of PTSD in patients who were hospitalized for COVID-19. Inclusion criteria were COVID-19 patients hospitalized in the intensive care unit (ICU) or in a standard unit with at least 2 L/min oxygen. Six months post-hospitalization, subjects were assessed for PTSD using a validated screening tool, the Post-Traumatic Stress Checklist-5 (PCL-5). Results: A total of 40 patients were included. No demographic differences between the ICU and non-ICU groups were found. The mean PCL-5 score for the population was 8.85±10. The mean PCL-5 score was 6.7±8 in the ICU group and 10.5±11 in the non-ICU group (P=0.27). We screened one patient with a positive PCL-5 score and one with a possible PCL-5 cluster score. Nine patients had a PCL-5 score of up to 15. Seven patients reported no symptoms. Seven patients accepted a psychological follow-up: one for PTSD, three for possible PTSD and three for other psychological problems. Discussion: The PCL-5 tool can be used by lung physicians during consultations to identify patients for whom follow-up mental health assessment and treatment for PTSD are warranted. Conclusion: Lung physicians should be aware of the risk of PTSD in patients hospitalized for COVID-19 and ensure appropriate screening and follow-up care.

2.
Sarcoidosis Vasc Diffuse Lung Dis ; 33(2): 117-23, 2016 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-27537713

RESUMO

BACKGROUND: The purpose of this study was to evaluate the use of high-resolution chest computed tomography (HRCT) to distinguish hypersensitivity pneumonitis (HP) from other diffuse parenchymal lung diseases (DPLDs). METHODS: We examined 130 consecutive patients admitted to our hospital with DPLDs proved by HRCT. Patients underwent clinical and paraclinical examinations. Two readers interpreted 111 HRCT scans using predefined criteria. RESULTS: The findings in patients with HP were compared to those with other DPLDs (non-HP) by univariate and multivariate analyses. Five independent radiological predictors were identified and were given a weight according to their regression coefficient: ground-glass attenuation nodules (4 points), homogeneous ground-glass opacity (3 points), patchy ground-glass opacity (2 points), absence of adenopathy (2 points), and absence of linear/reticular patterns (2 points). A total score (that we called "diagnostic index") of 5 offered the best trade-off between sensitivity and specificity. At this point of the ROC curve, the sensitivity, specificity, and likelihood ratio were 74%, 90% and 7.7, respectively. Given a pre-test probability of HP of 34% (i.e., 38 HP / 111 patients), the post-test probability was 79%. CONCLUSION: Our results provide evidence that HRCT can accurately distinguish HP from other DPLDs.


Assuntos
Alveolite Alérgica Extrínseca/diagnóstico por imagem , Pulmão/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Área Sob a Curva , Distribuição de Qui-Quadrado , Diagnóstico Diferencial , França , Humanos , Modelos Logísticos , Análise Multivariada , Variações Dependentes do Observador , Valor Preditivo dos Testes , Estudos Prospectivos , Curva ROC , Reprodutibilidade dos Testes
3.
Chest ; 146(3): 686-708, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24626791

RESUMO

BACKGROUND: Health-related quality of life (HRQoL) is severely impaired in pulmonary arterial hypertension (PAH). We aimed to assess the effect of PAH-specific therapies on HRQoL. METHODS: A literature search was performed in MEDLINE and Embase databases (January 1990 to September 2013) to retrieve prospective placebo-controlled randomized trials of at least 6 weeks duration reporting the effect of PAH-specific therapies on HRQoL in adult patients with PAH. The articles were independently reviewed, and the validity of the trials was assessed using the Cochrane's Risk of Bias Tool. RESULTS: The literature search identified 1,172 titles. Seventeen articles reporting on 14 trials were retrieved, all of which were associated with a low risk of bias. The median study duration of the different trials was 12 weeks. Most patients had idiopathic PAH or PAH associated with connective tissue disease. A variety of HRQoL questionnaires were used in these trials, and most were generic. HRQoL results were most commonly minimally detailed, and some pivotal trials did not even assess HRQoL. Nevertheless, these trials consistently demonstrated statistically significant improvements in HRQoL with PAH-specific therapies, especially for the physical domains. In most cases, however, these improvements were smaller than the minimal important difference in HRQoL previously reported in PAH. CONCLUSION: This review shows that PAH-specific therapies improve HRQoL in PAH. However, it remains difficult to draw any firm conclusion about the clinical significance of these improvements. Further work is mandatory to validate PAH-specific questionnaires that are responsive to clinical changes as well as to establish their interpretability.


Assuntos
Hipertensão Pulmonar Primária Familiar/tratamento farmacológico , Hipertensão Pulmonar Primária Familiar/psicologia , Qualidade de Vida/psicologia , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Reprodutibilidade dos Testes , Inquéritos e Questionários , Resultado do Tratamento
5.
Crit Care ; 15(3): R125, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21575205

RESUMO

INTRODUCTION: Among the various methods for improving oxygenation while decreasing the risk of ventilation-induced lung injury in patients with acute respiratory distress syndrome (ARDS), a ventilation strategy combining prone position (PP) and recruitment manoeuvres (RMs) can be practiced. We studied the effects on oxygenation of both RM and PP applied in early ARDS patients. METHODS: We conducted a prospective study. Sixteen consecutive patients with early ARDS fulfilling our criteria (ratio of arterial oxygen partial pressure to fraction of inspired oxygen (PaO2/FiO2) 98.3 ± 28 mmHg; positive end expiratory pressure, 10.7 ± 2.8 cmH2O) were analysed. Each patient was ventilated in both the supine position (SP) and the PP (six hours in each position). A 45 cmH2O extended sigh in pressure control mode was performed at the beginning of SP (RM1), one hour after turning to the PP (RM2) and at the end of the six-hour PP period (RM3). RESULTS: The mean arterial oxygen partial pressure (PaO2) changes after RM1, RM2 and RM3 were 9.6%, 15% and 19%, respectively. The PaO2 improvement after a single RM was significant after RM3 only (P < 0.05). Improvements in PaO2 level and PaO2/FiO2 ratio were transient in SP but durable during PP. PaO2/FiO2 ratio peaked at 218 mmHg after RM3. PaO2/FiO2 changes were significant only after RM3 and in the pulmonary ARDS group (P = 0.008). This global strategy had a benefit with regard to oxygenation: PaO2/FiO2 ratio increased from 98.3 mmHg to 165.6 mmHg 13 hours later at the end of the study (P < 0.05). Plateau airway pressures decreased after each RM and over the entire PP period and significantly after RM3 (P = 0.02). Some reversible side effects such as significant blood arterial pressure variations were found when extended sighs were performed. CONCLUSIONS: In our study, interventions such as a 45 cmH2O extended sigh during PP resulted in marked oxygenation improvement. Combined RM and PP led to the highest increase in PaO2/FiO2 ratio without major clinical side effects.


Assuntos
Respiração com Pressão Positiva/métodos , Decúbito Ventral/fisiologia , Síndrome do Desconforto Respiratório/fisiopatologia , Síndrome do Desconforto Respiratório/terapia , Idoso , Gasometria , Humanos , Pessoa de Meia-Idade , Oxigênio/química , Estudos Prospectivos , Decúbito Dorsal/fisiologia , Resultado do Tratamento
6.
Presse Med ; 35(6 Pt 1): 980-2, 2006 Jun.
Artigo em Francês | MEDLINE | ID: mdl-16783258

RESUMO

INTRODUCTION: Intravesical bacillus Calmette-Guerin (BCG) therapy, recommended for superficial bladder tumors, triggers side effects in fewer than 5% of patients. The most severe side effects, however, are septic shock and acute respiratory failure. CASE: A 70-year-old man was hospitalized for septic shock with acute respiratory and renal failure after intravesical instillation of BCG, which was identified in the gastric aspiration sample. Treatment with rifampicin, ethambutol, isoniazid, and corticosteroid therapy, as well as standard reanimation measures, led to the patient's recovery. DISCUSSION: This case shows the potentially severe side effects of intravesical BCG instillation. Although this treatment is well tolerated in more than 95% of patients and its systemic complications can be effectively treated, these side effects can be life-threatening.


Assuntos
Vacina BCG/efeitos adversos , Mycobacterium bovis/isolamento & purificação , Insuficiência Respiratória/microbiologia , Choque Séptico/microbiologia , Doença Aguda , Administração Intravesical , Idoso , Antibacterianos/uso terapêutico , Vacina BCG/administração & dosagem , Ceftriaxona/uso terapêutico , Humanos , Masculino , Ofloxacino/uso terapêutico , Insuficiência Respiratória/tratamento farmacológico , Neoplasias da Bexiga Urinária/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...